一种胰岛素新型集中化远程输注管理方法及系统
By adopting a dual-platform architecture that separates monitoring and intervention and using WebSocket long connections in the remote insulin infusion system, the problems of unreliable communication and complex operation in existing systems are solved, achieving efficient and secure centralized management and improving the reliability and security of remote infusion.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHENZHEN AIBAOWEI BIOTECHNOLOGY CO LTD
- Filing Date
- 2026-05-09
- Publication Date
- 2026-07-17
AI Technical Summary
Existing remote insulin infusion management systems suffer from problems in clinical applications, such as unreliable communication, complex operation, significant safety risks, and inability to adapt to centralized management, resulting in low treatment efficiency and insufficient safety.
It adopts a dual-platform architecture that separates monitoring and intervention, uses WebSocket long connections to replace traditional SMS communication, and combines identity verification, distributed concurrent locks, and multiple security mechanisms to build a closed-loop control for the entire process, realizing automated cloud collection and real-time monitoring of data.
It significantly improves the reliability and safety of remote insulin infusion, supports unified monitoring of multiple patients, lowers the operational threshold, enables efficient centralized management, and enhances medical work efficiency and system security.
Smart Images
Figure CN122177404B_ABST